Q-State is a discovery stage therapeutics and technology company advancing programs for the treatment of epilepsy, pain, and other disorders of the central nervous system.
Traditional drug discovery efforts for CNS disorders have significant limitations. The CNS is uniquely complex and just as uniquely challenging to modulate with therapeutics, and a translational gap exists where cell and animal models typically fail to reproduce human biology. We have built our platform to traverse this gap.
We integrate powerful enabling technologies along three axes—human biology, measurement engineering, and algorithmic analysis—into a proprietary platform that enables novel discovery of optimized genetically targeted medicines.
Our proprietary suite of technologies enables the opportunity to identify optimized therapeutics for challenging diseases of the CNS. We are quickly progressing 12 programs with plans to enter clinical trials for one of our lead candidates later this year.
Steven Hyman, MD, PhD
Director, Stanley Center for Psychiatric Research at the Broad Institute
Dr. Jonathan Thomas
Governing Board Chair, California Institute for Regenerative Medicine